Das George-Huntington-Institut

Dr. Reilmann presents in symposium at MDS 2019 in Nice

Dr. Reilmann (GHI) outlined the opportunities of quantitative endpoints for clinical trials in Huntington's disease at a symposium of the International Parkinson and Movement Disorders Society annual meeting 2019 in Nice, France. He was joined by Dr. Edward Wild, London, UK. Prof. Baas Bloem, Nijmegen, Netherlands, and Prof. Tanya Simuni, Chicago, USA, made the case for Parkinson's disease. A vivid panel discussion stressed the novel opportunities of objective devices. The event was support by an eductional grant of Hoffmann-La Roche.

Roche Studie Generation-HD1 stoppt weitere Dosierung
March 22, 2021

Die Firma Roche hat in einer Pressemeldung mitgeteilt, dass die Generation-HD1 Studie mit dem...

Read More
PROOF-HD phase III pivotal trial with Pridopidine
September 30, 2020

GHI will shortly start the pivotal phase III trial PROOF-HD with Pridopidine. Several studies...

Read More
SHIELD-HD Study of Triplet Therapeutics started at GHI
September 24, 2020

nan

Read More
Erreichbarkeit während der Umzugsphase
June 22, 2020

Liebe Patienten, Angehörige und Interessenten,

 

aufgrund des Umzugs sind die...

Read More
IDEA-FAST consortium receives € 44 Mio. from EU IMI2/Horizon 2020 program - GHI partner
December 6, 2019

The IMI2 consortium IDEA-FAST receives € 44 Mio. funding in the Horizon 2020 programm of the...

Read More